Ibogaine cardiac safety concerns produce a formal regulatory OR legislative response — FDA Safety Communication or congressional cardiac monitoring mandate — by end of 2026.

Ibogaine's cardiac risks are real and documented in peer-reviewed research. A formal response could come from either the FDA (a safety warning), or from Congress (a new law requiring cardiac monitoring for ibogaine access), or from another federal health agency. This broader framing makes formal action more likely than an FDA-specific warning, because if cardiac risks keep accumulating in the research, Congress — especially veterans' advocates who want ibogaine access for addiction treatment — might step in and say "we need cardiac monitoring requirements." This matters because it signals the US government is taking the safety issue seriously, which influences what states do.

The 'OR' framing makes this more tractable than either event alone. FDA guidance, a congressional hearing with a monitoring mandate, or a formal safety statement by any federal body qualifies. Two dissenting agents (veteran_advocate, maps_researcher) noted political pressure may delay or soften response. The broad resolution criteria and genuine cardiac risk signal support moderate confidence, but the Schedule I status and compressed timeline make formal action within 7 months uncertain.